Dermata Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
DRMA$0.77+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| For the three months ended March 31, | ||||
|---|---|---|---|---|
| 2026 · 2025 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $(1,847,706) | $(2,303,587) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation | 43,278 | 37,189 | ||
| Increase (decrease) in cash resulting from changes in: | ||||
| Prepaid expenses and other current assets | (85,431) | 86,579 | ||
| Inventory | (93,091) | - | ||
| Accounts payable | (51,128) | 102,064 | ||
| Accrued and other current liabilities | (445,640) | 143,689 | ||
| Net cash used in operating activities | (2,479,718) | (1,934,066) | ||
| Cash flows from financing activities: | ||||
| Proceeds from issuance of Common Stock from ATM sales, net of issuance costs | 1,994,374 | - | ||
| Proceeds from issuance of Common Stock, pre-funded warrants, and warrants, net of issuance costs | - | 8,541,282 | ||
| Proceeds from exercise of pre-funded warrants | - | 977 | ||
| Payment of issuance costs | (91,352) | (50,495) | ||
| Net cash provided by financing activities | 1,903,022 | 8,491,764 | ||
| Net increase (decrease) in Cash and cash equivalents | (576,696) | 6,557,698 | ||
| Cash and cash equivalents at beginning of period | 7,521,978 | 3,161,570 | ||
| Cash and cash equivalents at end of period | $6,945,282 | $9,719,268 | ||
| Non-cash financing activities: | ||||
| Issuance Common Stock upon exercise of pre-funded warrants | $54 | $ | - | |
| ATM issuance costs in accrued expenses | $323 | $ | - | |
| January 2025 PIPE issuance costs in accounts payable | $ | - | $79,102 | |
| March 2025 Warrant Inducement issuance costs in accounts payable | $ | - | $456,631 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.